Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...

Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

The project has four roving clinics that influencers are contracted to visit to brand HIV prevention as hip and ‘cool’ ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...